Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
Adipose-derived stem cell therapy is a form of regenerative medicine that utilizes your body’s own cells to support its natural repair processes. When administered via intravenous (IV) infusion, these cells embark on a complex journey within the body. A common question from patients is, “How long does it take to work?” Understanding the timeline of potential effects is key to setting realistic expectations. This article provides a general overview of what happens after an infusion and the gradual nature of the cellular processes involved.
A Gradual Journey, Not an Instant Fix
The primary takeaway is that the effects of adipose stem cell therapy are not immediate. The process involves a cascade of biological events that unfold over weeks and months. The goal is to support the body’s own healing capabilities by reducing inflammation and providing trophic support to damaged tissues. The timeline and extent of any perceived effects can vary significantly from person to person, depending on their health condition, age, and lifestyle. A thorough consultation with a physician is essential to understand the potential outcomes for your specific situation.
Common Questions About the Stem Cell Therapy Timeline
Patients considering this treatment often have similar concerns about the process. It’s natural to wonder:
- What happens immediately after the IV infusion?
- How long do the stem cells stay active in my body?
- When might I begin to notice any changes?
- Are the effects permanent?
This article will address these points by breaking down the therapeutic process into distinct phases, based on the reported actions of mesenchymal stem cells (MSCs).
Phase 1: The Initial Hours to Days – The Homing Effect
Immediately following the IV infusion, the administered mesenchymal stem cells enter the bloodstream and circulate throughout the body. Their first critical task is to navigate to areas that need support. This process is known as the “homing effect.” Research suggests that MSCs are attracted to chemical signals released by sites of inflammation or tissue damage. Within hours to a few days, a portion of the infused cells are expected to accumulate in these target areas. This initial phase is a silent, cellular-level event that you will not feel, but it is the foundation for all subsequent actions.
Phase 2: The First Few Weeks – Anti-Inflammatory Action
Once the MSCs have arrived at their target tissues, they begin to exert their influence on the local environment. One of their most well-documented functions is modulating inflammation. MSCs secrete a variety of anti-inflammatory molecules (cytokines and growth factors) that can help calm chronic or excessive inflammation. This is not about eliminating inflammation entirely, as some inflammation is necessary for healing, but rather about restoring a healthier balance. This immunomodulatory effect unfolds over the first few weeks post-infusion. During this period, the primary action is to create a more favorable environment for the body’s own repair mechanisms to function effectively.
Phase 3: The Following Months – Tissue Support and Repair
The longer-term potential of stem cell therapy lies in its ability to support tissue repair. This is largely achieved through what is known as the “trophic effect.” Rather than simply replacing damaged cells, MSCs act as on-site managers, releasing a wide range of growth factors and signaling molecules. These substances can encourage the surrounding native cells to proliferate, protect them from further damage, and support the formation of new blood vessels (angiogenesis) to improve blood supply. This supportive process is gradual and can continue for several months after the initial infusion. The goal is to enhance the body’s intrinsic ability to regenerate and maintain tissue health over time.
What to Know Before Your Consultation in Osaka
It is crucial to understand that individual results are not guaranteed and can be influenced by many factors, including the patient’s specific health condition, age, and lifestyle. Adipose-derived stem cell therapy is a treatment provided as a private, non-insured medical service. In Japan, this type of treatment is regulated under the Act on the Safety of Regenerative Medicine to ensure proper safety management. Before proceeding, a physician must conduct a thorough examination to determine if you are a suitable candidate. During your consultation, be prepared to discuss your medical history, current treatments, and your health goals. This will help the doctor provide a realistic perspective on what the treatment may or may not be able to achieve for you.
Learn More About Our Adipose-Derived Stem Cell Therapy
Understanding the full scope of any medical treatment is essential. For detailed information about how adipose-derived stem cell therapy is performed at Grand Green Osaka Umekita Clinic, including the flow of treatment, potential risks, side effects, and associated costs, please review our comprehensive treatment page. This information will help you make a well-informed decision in consultation with our physicians.
→ Learn more about Adipose-Derived Stem Cell Therapy
Summary: A Gradual Process of Cellular Support
The timeline of adipose stem cell therapy effects is a journey of gradual, cellular-level support. It begins with the homing of cells to target areas, followed by weeks of anti-inflammatory action, and extends into months of trophic support for tissue repair. It is not a quick fix but an approach aimed at enhancing your body’s own regenerative potential. If you are interested in exploring whether this regenerative medicine option is right for you, we invite you to schedule a consultation at Grand Green Osaka Umekita Clinic to discuss your health with our medical team.
References
- PubMed: Wharton's jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report. (2013)
- PMC: Isolation of Secretome with Enhanced Antifibrotic Properties from miR-214-Transfected Adipose-Derived Stem Cells. (2019)
- PMC: Progress and application of adipose-derived stem cells in the treatment of diabetes and its complications. (2024)
- PMC: In situ transplantation of adipose-derived stem cells via photoactivation improves glucose metabolism in obese mice. (2021)
- PMC: Therapeutic angiogenesis of adipose-derived stem cells for ischemic diseases. (2017)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.